Document Detail


Diabetes correction in pancreatectomized canines by orally absorbable insulin-deoxycholate complex.
MedLine Citation:
PMID:  20361761     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Oral insulin therapy has great potential benefits over conventional therapy for diabetic patients as well as mimicking the physiological fate of insulin. Here we evaluated the characteristics of insulin and deoxycholate-based synthetic N(alpha)-deoxycholyl-L-lysyl-methylester (DCK) complex, and diabetes correction in pancreatectomized canines after oral administration. After the insulin/DCK complexation was made, the insulin's folding structure, stability against digestive enzymes, lipophilicity and permeability to Caco-2 monolayer were evaluated in vitro. Diabetic canines were kept under fasting conditions, and Eudragit-coated gelatin capsules containing insulin or insulin/DCK powder were singly or triply administered. Evaluation of glucodynamics, pharmacokinetics, oral glucose tolerance test (OGTT) and reproducibility were carried out. After complexation with DCK, the folding structure of insulin did not become denatured and the resistance against digestive enzymes was powerfully improved. The lipophilicity and permeability of insulin/DCK (coupling ratio up to 1:10) were also highly increased. The insulin/DCK complex, administered orally into diabetic canines at the doses of 21, 42, and 81 IU/kg, reduced the plasma glucose levels by about 28%, 44% and 67%, respectively, while the plasma insulin concentrations increased. During OGTT, insulin/DCK nearly maintained the normoglycemic state in the diabetic canines, whereas the hyperglycemic state of placebo-treated controls was not corrected. During oral administration of insulin/DCK, it repetitively showed similar therapeutic efficacy in diabetic canines for 3 days. The therapeutic efficacy of insulin/DCK was exhibited in its digestive enzyme resistance, deoxycholate-based lipophilicity for enhancing permeability and intact insulin delivery without chemical modification, providing potential oral therapeutic remedy as an alternative to injectable insulin medication.
Authors:
Sang Kyoon Kim; Seulki Lee; Sunji Jin; Hyun Tae Moon; Ok Cheol Jeon; Dong Yun Lee; Youngro Byun
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Molecular pharmaceutics     Volume:  7     ISSN:  1543-8392     ISO Abbreviation:  Mol. Pharm.     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-06-07     Completed Date:  2010-09-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101197791     Medline TA:  Mol Pharm     Country:  United States    
Other Details:
Languages:  eng     Pagination:  708-17     Citation Subset:  IM    
Affiliation:
College of Pharmacy, Seoul National University, Seoul 151-742, South Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Animals
Blood Glucose / drug effects
Caco-2 Cells
Cholagogues and Choleretics / pharmacology,  therapeutic use
Deoxycholic Acid / administration & dosage,  chemistry,  therapeutic use*
Diabetes Mellitus / blood,  drug therapy*
Dogs
Glucose Tolerance Test
Humans
Hypoglycemic Agents / pharmacology,  therapeutic use
Insulin / chemistry,  pharmacokinetics,  therapeutic use*
Male
Pancreatectomy*
Chemical
Reg. No./Substance:
0/Blood Glucose; 0/Cholagogues and Choleretics; 0/Hypoglycemic Agents; 11061-68-0/Insulin; 83-44-3/Deoxycholic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Predicting the formation and stability of amorphous small molecule binary mixtures from computationa...
Next Document:  Surface Functionalization of Titanium with Chitosan/Gelatin via Electrophoretic Deposition: Characte...